Johnson & Johnson vs Merck — CEO Pay Comparison
Joaquin Duato (Johnson & Johnson) earns $0 more in total compensation than Rob Davis (Merck).
| Metric | Johnson & JohnsonJNJ | MerckMRK |
|---|---|---|
| CEO | Joaquin Duato | Rob Davis |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Total Compensation | $12.0M | $12.0M |
| Base Salary | $1.2M | $1.2M |
| Stock Awards | $6.0M | $6.0M |
| Option Awards | $1.4M | $1.4M |
| Non-Equity Incentive | $1.8M | $1.8M |
| Pay-for-Performance Grade | B (68/100) | B (71/100) |
| CEO-Worker Pay Ratio | 120:1 | 120:1 |
| Median Worker Pay | $100K | $100K |
| Say-on-Pay Approval | 94.8% | 94.6% |
| 3yr Total Shareholder Return | +1.4% | +11.7% |
| Revenue | $85.2B | $60.1B |
| Market Cap | $370.0B | $280.0B |
| Employees | 131,900 | 69,000 |
Analysis
Joaquin Duato (Johnson & Johnson) earns $12.0M in total compensation, while Rob Davis (Merck) earns $12.0M.
On pay-for-performance alignment, Johnson & Johnson scores B (68/100) while Merck scores B (71/100). Merck's CEO compensation is better aligned with company performance.
Johnson & Johnson's CEO-to-worker pay ratio is 120:1 compared to Merck's 120:1. Shareholders approved CEO pay at 94.8% (Johnson & Johnson) and 94.6% (Merck).